Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome

Irritable Colon Clinical Trial

Official title:
A Phase IIa Pharmacodynamic Study of Antagonism of Irritable Bowel Syndrome (IBS) Symptoms by GW876008, a Corticotrophin Releasing Factor 1 Receptor Antagonist (CRF1-RA)

Status Completed

Clinical Trial Summary

The purpose of this study is to see if GW876008 in Irritable Bowel Syndrome patients will reverse stress-induced hypersensitivity, by looking at thresholds for perception and pain.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00385099
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 2
Start date	December 8, 2006
Completion date	October 15, 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01855711` - Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)	Phase 2
Terminated	`NCT00423345` - Colon Investigation - Factors Determining Choice of Procedure
Completed	`NCT00101985` - Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)	Phase 2
Completed	`NCT00376896` - Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers	Phase 1
Completed	`NCT00067457` - Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy	Phase 3
Completed	`NCT00067561` - Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy	Phase 3
Terminated	`NCT00461682` - Sb-705498 Rectal Pain Study	Phase 2
Completed	`NCT00370032` - Study to Assess the Effect Of Alosetron On Mucosal Blood Flow	Phase 4